CN111526878A - 含三萜类化合物的药物组合物及其用途 - Google Patents

含三萜类化合物的药物组合物及其用途 Download PDF

Info

Publication number
CN111526878A
CN111526878A CN201880084560.6A CN201880084560A CN111526878A CN 111526878 A CN111526878 A CN 111526878A CN 201880084560 A CN201880084560 A CN 201880084560A CN 111526878 A CN111526878 A CN 111526878A
Authority
CN
China
Prior art keywords
substituted
compound
unsubstituted
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880084560.6A
Other languages
English (en)
Inventor
郑钦元
朱敬杰
曲婧
罗煜
丁时澄
秦丽军
周想燕
孙传民
赵芬琴
张存清
季中伟
郭丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Selleck Chemicals Co ltd
Original Assignee
Shanghai Selleck Chemicals Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201711489391.8A external-priority patent/CN109985052A/zh
Priority claimed from CN201711480630.3A external-priority patent/CN109985050A/zh
Priority claimed from CN201711484482.2A external-priority patent/CN109985071A/zh
Priority claimed from CN201711480659.1A external-priority patent/CN109985051A/zh
Application filed by Shanghai Selleck Chemicals Co ltd filed Critical Shanghai Selleck Chemicals Co ltd
Publication of CN111526878A publication Critical patent/CN111526878A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种三萜类化合物的新用途。具体地，本发明提供了式I化合物、或其光学异构体或其外消旋体、或其溶剂化物、或其药学上可接受的盐、或其前药的用途，它们被用于制备药物组合物或制剂，所述药物组合物或制剂用于预防和/或治疗晶状体病变引起的眼部疾病。本发明首次发现了式I化合物能够预防和/或治疗晶状体病变引起的眼部疾病，如白内障的预防和治疗，且安全性高，毒副作用小并具有显著的治疗效果和开发应用前景。

Description

PCT国内申请，说明书已公开。

Claims (37)

  1. PCT国内申请，权利要求书已公开。
CN201880084560.6A 2017-12-29 2018-12-28 含三萜类化合物的药物组合物及其用途 Pending CN111526878A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2017114806591 2017-12-29
CN201711489391.8A CN109985052A (zh) 2017-12-29 2017-12-29 三萜类化合物的新用途
CN2017114844822 2017-12-29
CN2017114893918 2017-12-29
CN201711480630.3A CN109985050A (zh) 2017-12-29 2017-12-29 栓菌酸的新用途
CN2017114806303 2017-12-29
CN201711484482.2A CN109985071A (zh) 2017-12-29 2017-12-29 桦褐孔菌提取物的新用途
CN201711480659.1A CN109985051A (zh) 2017-12-29 2017-12-29 桦褐孔菌醇的新用途
PCT/CN2018/125075 WO2019129249A1 (zh) 2017-12-29 2018-12-28 含三萜类化合物的药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN111526878A true CN111526878A (zh) 2020-08-11

Family

ID=67066645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880084560.6A Pending CN111526878A (zh) 2017-12-29 2018-12-28 含三萜类化合物的药物组合物及其用途

Country Status (3)

Country Link
US (1) US20200384003A1 (zh)
CN (1) CN111526878A (zh)
WO (1) WO2019129249A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021010996A2 (pt) 2018-12-05 2021-08-31 Sage Therapeutics, Inc. Esteroides neuroativos e seus métodos de uso
CN110721190A (zh) * 2019-11-21 2020-01-24 中国热带农业科学院热带生物技术研究所 一种防治老年性痴呆的药物
CN113956320B (zh) * 2021-10-22 2022-12-30 中国热带农业科学院热带生物技术研究所 一种具有显著乙酰胆碱酯酶和丁酰胆碱酯酶抑制活性的三萜类化合物及其制备方法和应用
CN114591389B (zh) * 2022-03-14 2024-06-25 广州润尔眼科生物科技有限公司 一种甾体化合物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110101433A (ko) * 2010-03-08 2011-09-16 건국대학교 산학협력단 차가버섯 가수분해 효소 추출물을 함유하는 항산화 조성물
US20170218009A1 (en) * 2016-02-03 2017-08-03 Youhealth Biotech, Limited Compounds for treating eye disorders or diseases
CN107312053A (zh) * 2016-04-27 2017-11-03 清华大学 一种化合物及其在治疗白内障中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110101433A (ko) * 2010-03-08 2011-09-16 건국대학교 산학협력단 차가버섯 가수분해 효소 추출물을 함유하는 항산화 조성물
US20170218009A1 (en) * 2016-02-03 2017-08-03 Youhealth Biotech, Limited Compounds for treating eye disorders or diseases
CN107312053A (zh) * 2016-04-27 2017-11-03 清华大学 一种化合物及其在治疗白内障中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Triterpenoids from Inonotus obliquus and their antitumor activities" *
HONGHAI HU等: "Comparative study of antioxidant activity and antiproliferative effect of hot water and ethanol extracts from the mushroom Inonotus obliquus"" *
赵芬琴 等: "桦褐孔菌三萜对CCl4致小鼠氧化应激损伤的保护作用" *

Also Published As

Publication number Publication date
US20200384003A1 (en) 2020-12-10
WO2019129249A1 (zh) 2019-07-04

Similar Documents

Publication Publication Date Title
CN111526878A (zh) 含三萜类化合物的药物组合物及其用途
DE69232925T2 (de) Angiostatische steroide
CN101624414B (zh) 一种抑制血管新生的硝酸酯药物
CN104382848B (zh) 一种他克莫司混悬型滴眼液及其制备方法
EA032779B1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
WO2016150378A1 (zh) 一种含有水飞蓟宾、左旋肉碱的药物组合物
CN111789844B (zh) 一种吡嗪类化合物在制备药物中的应用
CN1931176A (zh) 七叶皂苷的药物组合物及其制备方法和其用途
JP2016513706A (ja) 点眼用製剤
CN110548037A (zh) 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途
JP2021536472A (ja) アネトールトリチオンおよびその誘導体のシクロデキストリン複合体を含む医薬組成物
CN111377993A (zh) 三萜类化合物的新用途
WO2017189953A1 (en) Poly(ketals) and related compositions and methods
JP2024501081A (ja) Ｒｏｃｋプロテアーゼインヒビターであるイソキノリノン型化合物の塩型及びその調製方法
JP3603129B2 (ja) 糖尿病性角膜症の治療剤
CN111793036B (zh) 一种吡嗪类化合物及其制备方法
EP2980096B1 (en) 2 ,3 ,5 -trihydroxy-androst-6-one and preparation methods and use thereof
JP2985007B2 (ja) 血管新生阻害剤
US20240058265A1 (en) Treatment of ocular diseases using endothelin receptor antagonists
CA3036065A1 (en) Crystalline forms of therapeutic compounds and uses thereof
EP4282401A1 (en) Ophthalmic preparation administered by eye drops and used for preventing and treating dry macular degeneration and retinal light damage
JP2925677B2 (ja) アリスモール関連化合物を有効成分とする肝臓疾患治療薬
CN104055728A (zh) 一种曲安奈德水凝胶眼用制剂的制备方法
US10253045B2 (en) Crystalline forms of a therapeutic compound and uses thereof
JP2023536938A (ja) ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200811

WD01 Invention patent application deemed withdrawn after publication